Related references
Note: Only part of the references are listed.Models of Excellence: Improving Oncology Drug Development
M. R. Sharma et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Simulations Using a Drug-Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non-Small-Cell Lung Cancer
L. Claret et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1
Giorgio V. Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Zhong-Zhen Guan et al.
Chinese Journal of Cancer (2012)
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer
N. Frances et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
Wilfred D. Stein et al.
CLINICAL CANCER RESEARCH (2011)
A Time to Keep and a Time to Cast Away Categories of Tumor Response
Michael L. Maitland et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer
Laurent Claret et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies
R. Bruno et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer
Theodore G. Karrison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
